{"schema_version":"secwatch.filing_event.v1","accession":"0000719135-23-000045","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.490049+00:00","generated_at":"2026-06-11T19:53:16.180955+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Apyx Medical Q2 revenue up 32% to $13.6M, net loss narrows 82% to $1.0M, reaffirms FY2023 guide","bullets":["Advanced Energy revenue rose 40% YoY to $11.7M; OEM revenue fell 4% to $1.8M.","Net loss improved to $1.0M ($0.03 loss per share) from $5.4M in Q2 2022.","Adjusted EBITDA loss decreased 52% to $1.6M; gross margin expanded to 68.4%.","FY2023 outlook reaffirmed: total revenue $59-62M, Advanced Energy $51-54M, net loss ~$10.5M.","Completed sale-leaseback of Clearwater facility, netting ~$6.6M; received two FDA 510(k) clearances in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0000719135-23-000045","json":"https://secwatch.observer/filing/0000719135-23-000045.json","markdown":"https://secwatch.observer/filing/0000719135-23-000045.md","text":"https://secwatch.observer/filing/0000719135-23-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000071913523000045/0000719135-23-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000071913523000045/apyx-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:53:16.180955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e74ad4309ab74fa2d44f885d47331d2550965598","claim":"Apyx Medical Corp reported second quarter ended June 30, 2023 results: revenue $13.6 million, net income Net loss attributable to stockholders of $1.0 million. Guidance reaffirmed.","evidence_excerpt":"second quarter ended June 30, 2023, and reaffirms financial expectations for the full year ending December 31, 2023. Second Quarter 2023 Financial Summary : • Total revenue of $13.6 million, up 32% year-over-year. ◦ Advanced Energy revenue of $11.7 million, up 40% year-over-year. ◦ OEM revenue of $1.8 million, down 4% year-over-year. • Net loss attributable to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913523000045/0000719135-23-000045-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$13.6 million"},{"label":"Net income","value":"Net loss attributable to stockholders of $1.0 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}